AI Visibility Snapshot · CMPS
How AI and terminals describe COMPASS Pathways plc
This snapshot is built only from your public SEC EDGAR record, the same machine-readable data that AI assistants and financial terminals read first. Confirmed facts only.
Ticker CMPS · CIK 0001816590 · generated October 27, 2026
We found 3 items that affect how AI and terminals describe CMPS.
SEC classification: Pharmaceutical Preparations (SIC 2834)
Worth checkingYour SEC industry code says "Pharmaceutical Preparations," while market data lists you under "Biotechnology." When classifications disagree, AI assistants and terminals pick one, and it is often the wrong one.
SEC records show a former name: Compass Rx Ltd.
Needs attentionEDGAR lists CMPS as formerly "Compass Rx Ltd." (through 2020-08-10). After a name change or reverse merger, AI engines and terminals routinely keep returning the old identity for the ticker. Investors searching COMPASS Pathways plc may be shown the prior company, its old business, and its old numbers.
Most recent SEC filing is about 78 days old
Worth checkingFiling activity has slowed since 2026-08-10. Fresh primary filings are the best raw material for how AI describes you.
Listed on Nasdaq
Looks cleanA national-exchange listing helps, but listed companies are still routinely misdescribed by AI assistants when their structured data is stale.
Get the full 24-hour AI Visibility audit
This page reads your public SEC record. The full Pulse IR audit adds what it cannot see: how ChatGPT, Perplexity, and Google AI actually answer "what is CMPS", how the major terminals (FactSet, S&P, Refinitiv, Bloomberg, TradingView) list you, whether you have a verified knowledge-graph entity, and the exact corrections to file. Delivered in 24 hours, free, no obligation. Enter your work email and we will send it.
For company management and investor relations. Pulse IR is the investor-relations firm behind PubCo Insight.
Every finding above is a confirmed public fact from SEC EDGAR. This is educational research about public data, not investment advice, and not a statement about the merits of the security.